试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-15
Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC)
编号:NCT03943550登记状态:提前终止企业 / 申办者:Hoffmann-La Roche
药物 / 成分:RO7049665、Placebo
登记的停止原因(原文):The decision to terminate study WP40161 was based on that treatment with RO7049665 showed trends in efficacy, however these data were below expectations and would not have supported superiority over standard of care.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-15
DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)
编号:NCT04276415登记状态:提前终止企业 / 申办者:Daiichi Sankyo
药物 / 成分:DS-6157a
登记的停止原因(原文):The study was terminated due to a business decision.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-15
Phase I Study of Marizomib + Panobinostat for Children With DIPG
编号:NCT04341311登记状态:提前终止企业 / 申办者:Dana-Farber Cancer Institute
药物 / 成分:Marizomib、Panobinostat
登记的停止原因(原文):Withdrawal of support from BMS
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-15
A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia
编号:NCT04638153登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:Recifercept
登记的停止原因(原文):The study was terminated due to lack of efficacy at any of the tested doses on 18th November 2022. The decision to terminate the study is not related to a safety concern.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-15
Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia
编号:NCT04679350登记状态:提前终止企业 / 申办者:ImmuneMed, Inc.
药物 / 成分:hzVSF-v13、Placebo (Normal saline solution)
登记的停止原因(原文):A new study combining Phase III clinical trials has been planned.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-15
18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer
编号:NCT04727736登记状态:提前终止企业 / 申办者:Ashok Muthukrishnan
药物 / 成分:18F-DCFPyL
登记的停止原因(原文):Intervention became FDA-approved
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-15
A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial
编号:NCT05205837登记状态:提前终止企业 / 申办者:Copenhagen University Hospital, Rigshospitalet
药物 / 成分:Letrozole 2.5mg, hCG、Placebo
登记的停止原因(原文):Lack of recruitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-15
Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases
编号:NCT05408871登记状态:提前终止企业 / 申办者:Yale University
药物 / 成分:adnectin 18F-BMS-986192 Head and Neck Cancer、adnectin 18F-BMS-986192 Brain Metastases
登记的停止原因(原文):PI changed institutions
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-14
A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes
编号:NCT02841540登记状态:提前终止企业 / 申办者:Hemavant Sciences GmbH
药物 / 成分:H3B-8800 (RVT-2001)
登记的停止原因(原文):The study was terminated after conducting an interim analysis of the available data where it became evident that the observed efficacy results were not in alignment with the initially set expectations.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-14
Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy
编号:NCT03179995登记状态:提前终止企业 / 申办者:Fox Chase Cancer Center
药物 / 成分:Octreotide、Placebo
登记的停止原因(原文):Grantor closed study
查看官方原始记录 ↗